The Eurasian Journal of Medicine

Current Pharmacological Approach to ARDS: The Place of Bosentan


Department of Pulmonary Disease, Ataturk University School of Medicine, Erzurum, Turkey

Eurasian J Med 2020; 52: 81-85
DOI: 10.5152/eurasianjmed.2020.19218
Read: 1210 Downloads: 443 Published: 27 February 2020

Acute respiratory distress syndrome is characterized by dyspnea at presentation, tachypnea on physical examination, findings of bilateral infiltration in chest radiography, refractory hypoxia, and high mortality. Although the main treatment approach is to address the underlying disease, there are also pharmacological and nonpharmacological options for supportive treatment. There is currently no pharmacological agent with proven efficacy in this syndrome, and many drugs are being studied for this purpose. One of these is the endothelin receptor antagonist bosentan.

Cite this article as: Araz O. Current Pharmacological Approach to ARDS: The Place of Bosentan. Eurasian J Med 2020; 52(1): 81-85.

EISSN 1308-8742